Evolent Health, Inc (NYSE:EVH) Given Average Rating of "Buy" by Analysts

Key Points

• Evolent Health, Inc. has received a consensus recommendation of "Buy" from fourteen research firms, with twelve analysts recommending a buy and one a strong buy.
• The company's stock price target averages approximately $17.93 among brokerages, while current trading is around $9.70.
• Evolent Health reported a quarterly EPS of $0.06, missing estimates, while revenue for the quarter was $483.65 million, exceeding analyst expectations.

Evolent Health, Inc (NYSE:EVH - Get Free Report) has been assigned an average rating of "Buy" from the fourteen brokerages that are covering the firm, Marketbeat reports. One analyst has rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $17.9286.

Several research firms recently commented on EVH. UBS Group upped their price objective on Evolent Health from $14.00 to $15.00 and gave the company a "buy" rating in a research note on Friday, May 9th. JMP Securities reiterated a "market outperform" rating and issued a $13.00 price target on shares of Evolent Health in a research report on Friday, June 20th. Needham & Company LLC reiterated a "buy" rating and issued a $15.00 price target on shares of Evolent Health in a research report on Tuesday, May 13th. Finally, Truist Financial boosted their price objective on Evolent Health from $14.00 to $16.00 and gave the company a "buy" rating in a research note on Thursday, July 17th.

Evolent Health Stock Performance

Evolent Health stock traded up $0.48 during trading on Friday, hitting $9.48. The stock had a trading volume of 598,969 shares, compared to its average volume of 2,538,199. Evolent Health has a 1 year low of $7.06 and a 1 year high of $33.63. The company has a quick ratio of 0.98, a current ratio of 0.98 and a debt-to-equity ratio of 0.69. The stock's 50 day moving average is $9.93 and its two-hundred day moving average is $9.64. The stock has a market cap of $1.11 billion, a price-to-earnings ratio of -6.02 and a beta of 0.82.

Evolent Health (NYSE:EVH - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The technology company reported ($0.10) EPS for the quarter, missing the consensus estimate of $0.10 by ($0.20). Evolent Health had a negative net margin of 5.94% and a positive return on equity of 1.78%. The firm had revenue of $444.33 million during the quarter, compared to analysts' expectations of $459.43 million. During the same quarter in the previous year, the company posted $0.30 EPS. Evolent Health's revenue for the quarter was down 31.3% on a year-over-year basis. As a group, analysts predict that Evolent Health will post 0.08 EPS for the current year.

Hedge Funds Weigh In On Evolent Health

Institutional investors have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC increased its stake in Evolent Health by 88.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,551 shares of the technology company's stock worth $29,000 after acquiring an additional 1,194 shares during the last quarter. Banque Cantonale Vaudoise bought a new position in shares of Evolent Health during the 1st quarter valued at about $25,000. Parallel Advisors LLC increased its position in shares of Evolent Health by 82.6% during the 2nd quarter. Parallel Advisors LLC now owns 3,487 shares of the technology company's stock valued at $39,000 after purchasing an additional 1,577 shares during the last quarter. Strs Ohio bought a new position in shares of Evolent Health during the 1st quarter valued at about $47,000. Finally, US Bancorp DE increased its position in shares of Evolent Health by 291.0% during the 1st quarter. US Bancorp DE now owns 5,153 shares of the technology company's stock valued at $49,000 after purchasing an additional 3,835 shares during the last quarter.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.